QQ客服 官方微博 反馈留言

	National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China
	Xue, Cong ; Hu, Zhihuang ; Jiang, Wei ; Zhao, Yuanyuan ; Xu, Fei ; Huang, Yan ; Zhao, Hongyun ; Wu, Jingxun ; Wu JX(吴敬勋) ; Zhang, Yang ; Zhao, Liping ; Zhang, Jing ; Chen, Likun ; Zhang, Li
	2012-08
关键词	Chemotherapy Chinese population Epidermal growth factor receptor Non-small cell lung cancer Practice pattern Survey
英文摘要	Introduction: Treatment choice for NSCLC in China has not previously been reported. This paper explores the clinical practice and adherence to treatment guidelines for NSCLC. Methods: A specifically designed questionnaire was used. It consisted of personal information of the responders and treatment details (patient identification data was excluded). Questionnaires were delivered to doctors in 12 major cities in China. Doctors were asked to answer the questionnaires based on real cases in their daily practice. Results: 987 cases of NSCLC were included. In first-line chemotherapy, regimens were mostly platinum-based among which gemcitabine plus platinum was predominately used (27.4%), followed by docetaxel plus platinum (16.2%) and paclitaxel plus platinum (13.5%). In second-line therapy some were treated with single agents, such as docetaxel (12.9%), gefitinib (11.1%), pemetrexed (9.3%), and erlotinib (3.5%). 44.5% were with doublet therapy. Detection rate of epidermal growth factor receptor (EGFR) mutation was only 9.6% because of the limited prevalence of testing technology. EGFR mutation rate was 46.8%. EGFR-tyrosine kinase inhibitors (TKIs) were used more frequently as salvage (14.8%) rather than upfront therapy (5.3%). Conclusions: This survey reveals the daily clinical treatment for NSCLC in China. Overall data showed modest adherence to the national guideline (NCCN guideline Chinese version) for first-line chemotherapy. We believe this survey is valuable to provide a reference for further clinical trial design and policy making. (C) 2012 Elsevier Ireland Ltd. All rights reserved.; Sanofi aventis; Science and Technology Commission of Guangzhou [2010J-E151]; Wu Jieping Medical Foundation [08-JC-003]
语种	英语
出版者	ELSEVIER IRELAND LTD
内容类型	期刊论文
源URL	[http://dx.doi.org/10.1016/j.lungcan.2012.04.014]
专题	医学院－已发表论文
推荐引用方式 GB/T 7714	Xue, Cong,Hu, Zhihuang,Jiang, Wei,et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China[J],2012.
APA	Xue, Cong.,Hu, Zhihuang.,Jiang, Wei.,Zhao, Yuanyuan.,Xu, Fei.,...&Zhang, Li.(2012).National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China..
MLA	Xue, Cong,et al."National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China".(2012).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。